{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:31:13Z","timestamp":1776753073675,"version":"3.51.2"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF 2017-83267-C2-1R"],"award-info":[{"award-number":["SAF 2017-83267-C2-1R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1038\/s41423-020-0464-1","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T11:03:00Z","timestamp":1589972580000},"page":"576-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-0836","authenticated-orcid":false,"given":"I\u00f1aki","family":"Etxeberria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elixabet","family":"Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asunta","family":"Cirella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"464_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"464_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62\u201368 (2015).","journal-title":"Science"},{"issue":"3","key":"464_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"Noriko Shimasaki","year":"2020","unstructured":"Shimasaki, N., Jain, A. & Campana D. NK cells for cancer immunotherapy. Nat. Rev. Drug. Discov. https:\/\/doi.org\/10.1038\/s41573-019-0052-1 (2020).","journal-title":"Nature Reviews Drug Discovery"},{"key":"464_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. New Engl. J. Med 382, 545\u2013553 (2020).","journal-title":"New Engl. J. Med"},{"key":"464_CR5","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res 17, 4550\u20134557 (2011).","journal-title":"Clin. Cancer Res"},{"key":"464_CR6","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen, R. et al. Long-Lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated il2 regimen. Clin. Cancer Res 22, 3734\u20133745 (2016).","journal-title":"Clin. Cancer Res"},{"key":"464_CR7","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. C. A. R. T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"464_CR8","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/nm1207-1411","volume":"13","author":"DM Pardoll","year":"2007","unstructured":"Pardoll, D. M. Building the bionic T cell. Nat. Med. 13, 1411\u20131413 (2007).","journal-title":"Nat. Med."},{"key":"464_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"464_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts, E. W. et al. Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 30, 324\u2013336 (2016).","journal-title":"Cancer Cell."},{"key":"464_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"464_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"464_CR13","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","volume":"188","author":"AJ Zajac","year":"1998","unstructured":"Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205\u20132213 (1998).","journal-title":"J. Exp. Med."},{"key":"464_CR14","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","volume":"22","author":"HM Zarour","year":"2016","unstructured":"Zarour, H. M. Reversing T-cell dysfunction and exhaustion in cancer. Clin. Cancer Res. 22, 1856\u20131864 (2016).","journal-title":"Clin. Cancer Res."},{"key":"464_CR15","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"J-M Chauvin","year":"2015","unstructured":"Chauvin, J.-M. et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J. Clin. Invest 125, 2046\u20132058 (2015).","journal-title":"J. Clin. Invest"},{"key":"464_CR16","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1172\/JCI98769","volume":"128","author":"X-Y Li","year":"2018","unstructured":"Li, X.-Y. et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J. Clin. Invest 128, 2613\u20132625 (2018).","journal-title":"J. Clin. Invest"},{"key":"464_CR17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion. Nat. Immunol.12, 492\u2013499 (2011).","journal-title":"Nat. Immunol."},{"key":"464_CR18","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.4049\/jimmunol.180.3.1309","volume":"180","author":"NS Joshi","year":"2008","unstructured":"Joshi, N. S. & Kaech, S. M. Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. J. Immunol. 180, 1309\u20131315 (2008).","journal-title":"J. Immunol."},{"key":"464_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-immunol-032712-095954","volume":"31","author":"SN Mueller","year":"2013","unstructured":"Mueller, S. N., Gebhardt, T., Carbone, F. R. & Heath, W. R. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev. Immunol. 31, 137\u2013161 (2013).","journal-title":"Annu Rev. Immunol."},{"key":"464_CR20","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1182\/blood-2006-10-051318","volume":"109","author":"A Perez-Diez","year":"2007","unstructured":"Perez-Diez, A. et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109, 5346\u20135354 (2007).","journal-title":"Blood"},{"key":"464_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"464_CR22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/30996","volume":"393","author":"SR Bennett","year":"1998","unstructured":"Bennett, S. R. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478\u2013480 (1998).","journal-title":"Nature"},{"key":"464_CR23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/31002","volume":"393","author":"SP Schoenberger","year":"1998","unstructured":"Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature393, 480\u2013483 (1998).","journal-title":"Nature"},{"key":"464_CR24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","volume":"47","author":"T Ahrends","year":"2017","unstructured":"Ahrends, T. et al. CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity 47, 848\u2013861.e5 (2017).","journal-title":"Immunity"},{"key":"464_CR25","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","volume":"358","author":"NN Hunder","year":"2008","unstructured":"Hunder, N. N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl. J. Med 358, 2698\u20132703 (2008).","journal-title":"N Engl. J. Med"},{"key":"464_CR26","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nm.2856","volume":"18","author":"R Purwar","year":"2012","unstructured":"Purwar, R. et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat. Med. 18, 1248\u20131253 (2012).","journal-title":"Nat. Med."},{"key":"464_CR27","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ccell.2018.05.004","volume":"33","author":"Y Lu","year":"2018","unstructured":"Lu, Y. et al. Th9 cells represent a unique subset of CD4(+) T cells endowed with the ability to eradicate advanced tumors. Cancer Cell. 33, 1048\u20131060.e7 (2018).","journal-title":"Cancer Cell."},{"key":"464_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","volume":"4","author":"I Melero","year":"2014","unstructured":"Melero, I., Rouzaut, A., Motz, G. T. & Coukos, G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Disco. 4, 522\u2013526 (2014).","journal-title":"Cancer Disco."},{"key":"464_CR29","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582\u2013598 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"464_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309\u2013322 (2012).","journal-title":"Cancer Cell"},{"issue":"1","key":"464_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"Kyohei Nakamura","year":"2019","unstructured":"Nakamura, K. & Smyth M. J. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol. Immunol. https:\/\/doi.org\/10.1038\/s41423-019-0306-1 (2019).","journal-title":"Cellular & Molecular Immunology"},{"key":"464_CR32","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1073\/pnas.0812851107","volume":"107","author":"D Busse","year":"2010","unstructured":"Busse, D. et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc. Natl Acad. Sci. USA 107, 3058\u20133063 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"464_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.02453","volume":"10","author":"CM Paluskievicz","year":"2019","unstructured":"Paluskievicz, C. M. et al. T regulatory cells and priming the suppressive tumor microenvironment. Front Immunol. 10, 1\u201315 (2019).","journal-title":"Front Immunol."},{"key":"464_CR34","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233\u20135239 (2008).","journal-title":"J. Clin. Oncol."},{"key":"464_CR35","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med 319, 1676\u20131680 (1988).","journal-title":"N. Engl. J. Med"},{"key":"464_CR36","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11912-012-0257-5","volume":"14","author":"S Lee","year":"2012","unstructured":"Lee, S. & Margolin, K. Tumor-infiltrating lymphocytes in melanoma. Curr. Oncol. Rep. 14, 468\u2013474 (2012).","journal-title":"Curr. Oncol. Rep."},{"key":"464_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-018-0391-1","volume":"6","author":"MW Rohaan","year":"2018","unstructured":"Rohaan, M. W., van den Berg, J. H., Kvistborg, P. & Haanen, J. B. A. G. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J. Immunother. Cancer 6, 102 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"464_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/imr.12134","volume":"257","author":"C Yee","year":"2014","unstructured":"Yee, C. The use of endogenous T cells for adoptive transfer. Immunol. Rev. 257, 250\u2013263 (2014).","journal-title":"Immunol. Rev."},{"key":"464_CR39","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246\u20132259(2014).","journal-title":"J. Clin. Invest."},{"key":"464_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","volume":"20","author":"Q Ye","year":"2014","unstructured":"Ye, Q. et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44\u201355 (2014).","journal-title":"Clin. Cancer Res."},{"key":"464_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433\u2013438 (2016).","journal-title":"Nat. Med."},{"key":"464_CR42","doi-asserted-by":"crossref","unstructured":"Fernandez-Poma, S. M. et al. Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T cell therapy. Cancer Res. http:\/\/cancerres.aacrjournals.org\/lookup\/doi\/10.1158\/0008-5472.CAN-17-0236 (2017)","DOI":"10.1158\/0008-5472.CAN-17-0236"},{"key":"464_CR43","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/eji.201545849","volume":"46","author":"S Kelderman","year":"2016","unstructured":"Kelderman, S. et al. Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy. Eur. J. Immunol. 46, 1351\u20131360 (2016).","journal-title":"Eur. J. Immunol."},{"key":"464_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"464_CR45","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00262-012-1378-2","volume":"62","author":"S Yang","year":"2013","unstructured":"Yang, S. et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol. Immunother. 62, 727\u2013736, (2013).","journal-title":"Cancer Immunol. Immunother."},{"key":"464_CR46","doi-asserted-by":"publisher","first-page":"e60031","DOI":"10.1371\/journal.pone.0060031","volume":"8","author":"JA Chacon","year":"2013","unstructured":"Chacon, J. A. et al. Co-stimulation through 4-1BB\/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS ONE 8, e60031\u2013e60031 (2013).","journal-title":"PLoS ONE"},{"key":"464_CR47","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.4049\/jimmunol.1102495","volume":"189","author":"S Hervas-Stubbs","year":"2012","unstructured":"Hervas-Stubbs, S. et al. CD8 T cell priming in the presence of IFN-\u03b1 renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J. Immunol. 189, 3299\u20133310 (2012).","journal-title":"J. Immunol."},{"key":"464_CR48","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907\u2013912 (2005).","journal-title":"J. Exp. Med."},{"key":"464_CR49","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","volume":"36","author":"N Arenas-Ramirez","year":"2015","unstructured":"Arenas-Ramirez, N., Woytschak, J. & Boyman, O. Interleukin-2: biology, design and application. Trends Immunol. 36, 763\u2013777 (2015).","journal-title":"Trends Immunol."},{"key":"464_CR50","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","volume":"112","author":"E Romano","year":"2015","unstructured":"Romano, E. et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl Acad. Sci. USA 112, 6140\u20136145 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"464_CR51","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"464_CR52","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","volume":"37","author":"AA Jazaeri","year":"2019","unstructured":"Jazaeri, A. A. et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J. Clin. Oncol. 37, 2538 (2019).","journal-title":"J. Clin. Oncol."},{"key":"464_CR53","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/PPO.0000000000000162","volume":"21","author":"LG Radvanyi","year":"2015","unstructured":"Radvanyi, L. G. Tumor-infiltrating lymphocyte therapy: addressing prevailing questions. Cancer J. 21, 450\u2013464 (2015).","journal-title":"Cancer J."},{"key":"464_CR54","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","volume":"18","author":"SS Chandran","year":"2017","unstructured":"Chandran, S. S. et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 18, 792\u2013802 (2017).","journal-title":"Lancet Oncol."},{"key":"464_CR55","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.breast.2017.07.005","volume":"35","author":"C Solinas","year":"2017","unstructured":"Solinas, C., Carbognin, L., De Silva, P., Criscitiello, C. & Lambertini, M. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: current state of the art. Breast 35, 142\u2013150 (2017).","journal-title":"Breast"},{"key":"464_CR56","doi-asserted-by":"publisher","first-page":"e1502905","DOI":"10.1080\/2162402X.2018.1502905","volume":"7","author":"M Pedersen","year":"2018","unstructured":"Pedersen, M. et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. Oncoimmunology 7, e1502905\u2013e1502905 (2018).","journal-title":"Oncoimmunology"},{"key":"464_CR57","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/imr.12772","volume":"290","author":"SS Chandran","year":"2019","unstructured":"Chandran, S. S. & Klebanoff, C. A. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunol. Rev. 290, 127\u2013147 (2019).","journal-title":"Immunol. Rev."},{"key":"464_CR58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).","journal-title":"Science"},{"key":"464_CR59","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can eradiate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620\u2013626 (2011).","journal-title":"Mol. Ther."},{"key":"464_CR60","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrc1669","volume":"5","author":"AJG Simpson","year":"2005","unstructured":"Simpson, A. J. G., Caballero, O. L., Jungbluth, A., Chen, Y.-T. & Old, L. J. Cancer\/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5, 615\u2013625 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"464_CR61","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924 (2011).","journal-title":"J. Clin. Oncol."},{"key":"464_CR62","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","volume":"35","author":"Y-C Lu","year":"2017","unstructured":"Lu, Y.-C. et al. Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J. Clin. Oncol. 35, 3322\u20133329 (2017).","journal-title":"J. Clin. Oncol."},{"key":"464_CR63","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron, B. J. et al. Identification of a titin-derived HLA-A1\u2013presented peptide as a cross-reactive target for engineered MAGE A3\u2013directed T cells. Sci. Transl. Med. 5, 197ra103 (2013).","journal-title":"Sci. Transl. Med."},{"key":"464_CR64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133\u2013151 (2013).","journal-title":"J. Immunother."},{"key":"464_CR65","doi-asserted-by":"publisher","first-page":"e99488","DOI":"10.1172\/jci.insight.99488","volume":"3","author":"BY Jin","year":"2018","unstructured":"Jin, B. Y. et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI insight 3, e99488 (2018).","journal-title":"JCI insight"},{"key":"464_CR66","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","volume":"4","author":"QJ Wang","year":"2016","unstructured":"Wang, Q. J. et al. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol. Res. 4, 204\u2013214(2016).","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"464_CR67","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-19-1874","volume":"26","author":"Parisa Malekzadeh","year":"2020","unstructured":"Malekzadeh, P. et al. Antigen experienced T cells from peripheral blood recognize p53 neoantigens. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1874 (2020)","journal-title":"Clinical Cancer Research"},{"key":"464_CR68","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1172\/JCI98689","volume":"128","author":"JR Veatch","year":"2018","unstructured":"Veatch, J. R. et al. Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. J. Clin. Invest. 128, 1563\u20131568 (2018).","journal-title":"J. Clin. Invest."},{"key":"464_CR69","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"464_CR70","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1158\/1078-0432.CCR-19-3813","volume":"26","author":"Irene Olivera","year":"2020","unstructured":"Olivera, I., Etxeberria, I., Bola\u00f1os, E., Gato-Ca\u00f1as, M., Melero I. Exploiting TCR recognition of shared hot-spot oncogene-encoded neoantigens. Clin. Cancer Res. 26, 1203\u20131204 (2020).","journal-title":"Clinical Cancer Research"},{"key":"464_CR71","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan, S., Calderon, H., Posey, A. D. & Maus, M. V. Engineering and design of chimeric antigen receptors. Mol. Ther. Methods Clin. Dev. 12, 145\u2013156 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"464_CR72","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Invest."},{"key":"464_CR73","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"1","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 1, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"464_CR74","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724\u2013740 (2017).","journal-title":"Cell"},{"key":"464_CR75","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.3389\/fimmu.2018.02593","volume":"9","author":"A Schmidts","year":"2018","unstructured":"Schmidts, A., Maus, M. V. & Making, C. A. R. T cells a solid option for solid tumors. Front Immunol. 9, 2593 (2018).","journal-title":"Front Immunol."},{"key":"464_CR76","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00262-016-1842-5","volume":"65","author":"TT Spear","year":"2016","unstructured":"Spear, T. T., Nagato, K. & Nishimura, M. I. Strategies to genetically engineer T cells for cancer immunotherapy. Cancer Immunol. Immunother. 65, 631\u2013649 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"464_CR77","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2174\/1381612824666171227222624","volume":"24","author":"Y-B Ren","year":"2018","unstructured":"Ren, Y.-B., Sun, S.-J. & Han, S.-Y. Safety strategies of genetically engineered T cells in cancer immunotherapy. Curr. Pharm. Des. 24, 78\u201383 (2018).","journal-title":"Curr. Pharm. Des."},{"key":"464_CR78","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2217\/imt.14.51","volume":"6","author":"SR Jackson","year":"2014","unstructured":"Jackson, S. R., Yuan, J. & Teague, R. M. Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunother. 6, 833\u2013852 (2014).","journal-title":"Immunother."},{"key":"464_CR79","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/eji.201242606","volume":"42","author":"M Aleksic","year":"2012","unstructured":"Aleksic, M. et al. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol. 42, 3174\u20133179 (2012).","journal-title":"Eur. J. Immunol."},{"key":"464_CR80","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1158\/1078-0432.CCR-08-1638","volume":"15","author":"MR Parkhurst","year":"2009","unstructured":"Parkhurst, M. R. et al. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin. Cancer Res. 15, 169\u2013180 (2009).","journal-title":"Clin. Cancer Res."},{"key":"464_CR81","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nbt1070","volume":"23","author":"Y Li","year":"2005","unstructured":"Li, Y. et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23, 349\u2013354 (2005).","journal-title":"Nat. Biotechnol."},{"key":"464_CR82","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"464_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20150304","volume":"212","author":"DC Palmer","year":"2015","unstructured":"Palmer, D. C. et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J. Exp. Med. 212, 1\u201319 (2015).","journal-title":"J. Exp. Med."},{"key":"464_CR84","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.4049\/jimmunol.1200552","volume":"189","author":"IM Stromnes","year":"2012","unstructured":"Stromnes, I. M. et al. Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo. J. Immunol. 189, 1812\u20131825 (2012).","journal-title":"J. Immunol."},{"key":"464_CR85","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1158\/0008-5472.CAN-12-3874","volume":"73","author":"MJ Riese","year":"2013","unstructured":"Riese, M. J. et al. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res. 73, 3566\u20133577 (2013).","journal-title":"Cancer Res."},{"key":"464_CR86","doi-asserted-by":"crossref","unstructured":"Brownlie, R. J., Wright, D., Zamoyska, R. & Salmond, R. J. Deletion of PTPN22 improves effector and memory CD8+ T cell responses to tumors. JCI Insight 4, e127847 (2019).","DOI":"10.1172\/jci.insight.127847"},{"key":"464_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-12544-4","volume":"10","author":"YR Thaker","year":"2019","unstructured":"Thaker, Y. R., Raab, M., Strebhardt, K. & Rudd, C. E. GTPase-activating protein Rasal1 associates with ZAP-70 of the TCR and negatively regulates T-cell tumor immunity. Nat. Commun. 10, 1\u201313 (2019).","journal-title":"Nat. Commun."},{"key":"464_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-09656-2","volume":"10","author":"MW LaFleur","year":"2019","unstructured":"LaFleur, M. W. et al. A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. Nat. Commun. 10, 1\u201310 (2019).","journal-title":"Nat. Commun."},{"key":"464_CR89","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","volume":"175","author":"E Shifrut","year":"2018","unstructured":"Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell 175, 1958\u20131971.e15 (2018).","journal-title":"Cell"},{"key":"464_CR90","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413\u2013418 (2017).","journal-title":"Nature"},{"key":"464_CR91","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature23477","volume":"548","author":"SJ Patel","year":"2017","unstructured":"Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537\u2013542 (2017).","journal-title":"Nature"},{"key":"464_CR92","doi-asserted-by":"crossref","unstructured":"Ramishetti S. & Peer D. Engineering lymphocytes with RNAi. Adv. Drug Deliv. Rev. 141, 55\u201366 (2019).","DOI":"10.1016\/j.addr.2018.12.002"},{"key":"464_CR93","doi-asserted-by":"publisher","first-page":"103878","DOI":"10.1016\/j.cellimm.2018.11.002","volume":"340","author":"R Tang","year":"2019","unstructured":"Tang, R., Langdon, W. Y. & Zhang, J. Regulation of immune responses by E3 ubiquitin ligase Cbl-b. Cell Immunol. 340, 103878 (2019).","journal-title":"Cell Immunol."},{"key":"464_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0044295","volume":"7","author":"R Hinterleitner","year":"2012","unstructured":"Hinterleitner, R. et al. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. PLoS ONE 7, 1\u20139 (2012).","journal-title":"PLoS ONE"},{"key":"464_CR95","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","volume":"25","author":"S Ramakrishna","year":"2019","unstructured":"Ramakrishna, S. et al. Modulation of target antigen density improves CAR T-cell functionality and persistence. Clin. Cancer Res. 25, 5329\u20135341 (2019).","journal-title":"Clin. Cancer Res."},{"key":"464_CR96","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"464_CR97","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove, R., George, P., Dasyam, N. & McLellan, A. D. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin. Transl. Immunol. 8, e1049\u2013e1049 (2019).","journal-title":"Clin. Transl. Immunol."},{"key":"464_CR98","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"P-L Chen","year":"2016","unstructured":"Chen, P.-L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Disco. 6, 827\u2013837 (2016).","journal-title":"Cancer Disco."},{"key":"464_CR99","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","volume":"72","author":"W Peng","year":"2012","unstructured":"Peng, W. et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible chemokines. Cancer Res. 72, 5209\u20135218 (2012).","journal-title":"Cancer Res."},{"key":"464_CR100","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/CJI.0000000000000064","volume":"38","author":"DA Mahvi","year":"2015","unstructured":"Mahvi, D. A. et al. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice. J. Immunother. 38, 54\u201361 (2015).","journal-title":"J. Immunother."},{"key":"464_CR101","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1158\/2326-6066.CIR-18-0873","volume":"7","author":"LZ Shi","year":"2019","unstructured":"Shi, L. Z. et al. Blockade of CTLA-4 and PD-1 enhances adoptive t-cell therapy efficacy in an ICOS-mediated manner. Cancer Immunol. Res. 7, 1803\u20131812 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"464_CR102","doi-asserted-by":"publisher","first-page":"7551","DOI":"10.1073\/pnas.1506357112","volume":"112","author":"B Weigelin","year":"2015","unstructured":"Weigelin, B. et al. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proc. Natl Acad. Sci. USA 112, 7551\u20137556 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"464_CR103","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.4049\/jimmunol.167.11.6669","volume":"167","author":"J Kjaergaard","year":"2001","unstructured":"Kjaergaard, J. et al. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 167, 6669\u20136677 (2001).","journal-title":"J. Immunol."},{"key":"464_CR104","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1349-7006.2009.01179.x","volume":"100","author":"N Imai","year":"2009","unstructured":"Imai, N. et al. Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression. Cancer Sci. 100, 1317\u20131325 (2009).","journal-title":"Cancer Sci."},{"key":"464_CR105","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/CJI.0b013e31824e7f43","volume":"35","author":"C Liu","year":"2012","unstructured":"Liu, C. et al. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J. Immunother. 35, 276\u2013282 (2012).","journal-title":"J. Immunother."},{"key":"464_CR106","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130\u20133144 (2016).","journal-title":"J. Clin. Invest."},{"key":"464_CR107","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","volume":"7","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J. Immunother. Cancer 7, 304 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"464_CR108","unstructured":"Stadtmauer, E. A., et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020)."},{"key":"464_CR109","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/nm1676","volume":"13","author":"MT Stephan","year":"2007","unstructured":"Stephan, M. T. et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440\u20131449 (2007).","journal-title":"Nat. Med."},{"issue":"25","key":"464_CR110","doi-asserted-by":"publisher","first-page":"eaat1482","DOI":"10.1126\/sciimmunol.aat1482","volume":"3","author":"Abul K. Abbas","year":"2018","unstructured":"Abbas, A. K., Trotta, E., R Simeonov, D., Marson, A., Bluestone J. A. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 3, eaat1482 (2018).","journal-title":"Science Immunology"},{"key":"464_CR111","unstructured":"Berraondo, P.,et al. Cytokines in clinical cancer immunotherapy. Br. J. Cancer https:\/\/www.nature.com\/articles\/s41416-018-0328-y (2018)."},{"key":"464_CR112","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037\u20131042 (2018).","journal-title":"Science"},{"key":"464_CR113","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"Shum, T. et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T Cells. Cancer Disco. 7, 1238\u20131247 (2017).","journal-title":"Cancer Disco."},{"key":"464_CR114","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541\u20132548 (1997).","journal-title":"Blood"},{"key":"464_CR115","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1172\/JCI58814","volume":"121","author":"SP Kerkar","year":"2011","unstructured":"Kerkar, S. P. et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746\u20134757 (2011).","journal-title":"J. Clin. Invest."},{"key":"464_CR116","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278\u20132288 (2015).","journal-title":"Clin. Cancer Res"},{"key":"464_CR117","first-page":"1","volume":"8","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. J. Immunother. 8, 1\u201312 (2020).","journal-title":"J. Immunother."},{"key":"464_CR118","doi-asserted-by":"publisher","first-page":"e1378842","DOI":"10.1080\/2162402X.2017.1378842","volume":"7","author":"A Kunert","year":"2017","unstructured":"Kunert, A. et al. Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. Oncoimmunology 7, e1378842\u2013e1378842 (2017).","journal-title":"Oncoimmunology"},{"key":"464_CR119","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4049\/jimmunol.1800033","volume":"203","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J. Immunol. 203, 198\u2013207 (2019).","journal-title":"J. Immunol."},{"key":"464_CR120","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton, L. V. et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl Acad. Sci. USA 113, E7788\u2013E7797 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"464_CR121","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. CAR T cells secreting IL18 augment antitumor immunity and increase T cell proliferation and costimulation 2. Cell Rep. 20, 3025\u20133033 (2017).","journal-title":"Cell Rep."},{"issue":"4","key":"464_CR122","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","volume":"38","author":"Xingcong Ma","year":"2020","unstructured":"Ma, X., et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat. Biotechnol.\nhttps:\/\/doi.org\/10.1038\/s41587-019-0398-2 (2020).","journal-title":"Nature Biotechnology"},{"key":"464_CR123","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","volume":"36","author":"I Etxeberria","year":"2019","unstructured":"Etxeberria, I. et al. Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8+ T Cells. Cancer Cell 36, 613\u2013629.e7 (2019).","journal-title":"Cancer Cell"},{"key":"464_CR124","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen, A. M. et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22, 1211\u20131220 (2014).","journal-title":"Mol. Ther."},{"key":"464_CR125","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/2159-8290.CD-17-1298","volume":"8","author":"S Sukumaran","year":"2018","unstructured":"Sukumaran, S. et al. Enhancing the potency and specificity of engineered T cells for cancer treatment. Cancer Disco. 8, 972\u2013987 (2018).","journal-title":"Cancer Disco."},{"key":"464_CR126","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"464_CR127","doi-asserted-by":"crossref","unstructured":"Tang, N. et al. TGF\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR-T cells against solid tumors. JCI insight 5, e133977 (2020).","DOI":"10.1172\/jci.insight.133977"},{"key":"464_CR128","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ni1197","volume":"6","author":"Y Laouar","year":"2005","unstructured":"Laouar, Y., Sutterwala, F. S., Gorelik, L. & Flavell, R. A. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat. Immunol. 6, 600\u2013607 (2005).","journal-title":"Nat. Immunol."},{"key":"464_CR129","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cell.2008.07.025","volume":"134","author":"MO Li","year":"2008","unstructured":"Li, M. O. & Flavell, R. A. TGF-beta: a master of all T cell trades. Cell 134, 392\u2013404 (2008).","journal-title":"Cell"},{"key":"464_CR130","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/imr.12135","volume":"257","author":"JG Crompton","year":"2014","unstructured":"Crompton, J. G., Sukumar, M. & Restifo, N. P. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol. Rev. 257, 264\u2013276 (2014).","journal-title":"Immunol. Rev."},{"key":"464_CR131","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41590-018-0311-z","volume":"20","author":"S Gautam","year":"2019","unstructured":"Gautam, S. et al. The transcription factor c-Myb regulates CD8 + T cell stemness and antitumor immunity. Nat. Immunol. 20, 337\u2013349 (2019).","journal-title":"Nat. Immunol."},{"key":"464_CR132","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534 (2019).","journal-title":"Nature"},{"key":"464_CR133","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo, H. et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc. Natl Acad. Sci. USA 116, 12410\u201312415 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"464_CR134","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"464_CR135","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei, J. et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature 576, 471\u2013476 (2019).","journal-title":"Nature"},{"key":"464_CR136","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41590-019-0480-4","volume":"20","author":"MW LaFleur","year":"2019","unstructured":"LaFleur, M. W. et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat. Immunol. 20, 1335\u20131347 (2019).","journal-title":"Nat. Immunol."},{"key":"464_CR137","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"464_CR138","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428, (2015).","journal-title":"Cancer Cell"},{"key":"464_CR139","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1158\/2326-6066.CIR-19-0115","volume":"7","author":"A Teijeira","year":"2019","unstructured":"Teijeira, A. et al. Metabolic consequences of T-cell costimulation in anticancer immunity. Cancer Immunol. Res. 7, 1564\u20131569 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"464_CR140","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","volume":"26","author":"RJ Kishton","year":"2017","unstructured":"Kishton, R. J., Sukumar, M. & Restifo, N. P. Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab. 26, 94\u2013109 (2017).","journal-title":"Cell Metab."},{"key":"464_CR141","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","volume":"162","author":"PC Ho","year":"2015","unstructured":"Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217\u20131228 (2015).","journal-title":"Cell"},{"key":"464_CR142","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ccell.2017.10.003","volume":"32","author":"A Palazon","year":"2017","unstructured":"Palazon, A. et al. An HIF-1\u03b1\/VEGF-A axis in cytotoxic T cells regulates tumor progression. Cancer Cell 32, 669\u2013683.e5 (2017).","journal-title":"Cancer Cell"},{"key":"464_CR143","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2017.08.004","volume":"32","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Enhancing CD8(+) T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell 32, 377\u2013391.e9 (2017).","journal-title":"Cancer Cell"},{"key":"464_CR144","doi-asserted-by":"publisher","unstructured":"Dumauthioz, N. et al. Enforced PGC-1\u03b1 expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell Mol. Immunol. https:\/\/doi.org\/10.1038\/s41423-020-0365-3 (2020)","DOI":"10.1038\/s41423-020-0365-3"},{"key":"464_CR145","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping, N. E. et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 374\u2013388 (2016).","journal-title":"Immunity"},{"key":"464_CR146","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380\u2013390 (2016).","journal-title":"Immunity"},{"key":"464_CR147","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/2326-6066.CIR-17-0767","volume":"6","author":"A Teijeira","year":"2018","unstructured":"Teijeira, A. et al. Mitochondrial morphological and functional reprogramming following CD137 (4-1BB) costimulation. Cancer Immunol. Res. 6, 798\u2013811 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"464_CR148","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.20171068","volume":"215","author":"AV Menk","year":"2018","unstructured":"Menk, A. V. et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J. Exp. Med. 215, 1091\u20131100 (2018).","journal-title":"J. Exp. Med."},{"key":"464_CR149","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. T. Cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. 4, 498\u2013508 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"464_CR150","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn, N. F. et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473\u2013488.e6 (2019).","journal-title":"Cancer Cell"},{"key":"464_CR151","doi-asserted-by":"publisher","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","volume":"28","author":"A.R. S\u00e1nchez-Paulete","year":"2017","unstructured":"S\u00e1nchez-Paulete, A. R. et al. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann. Oncol. 28, xii44\u2013xii55 (2017).","journal-title":"Annals of Oncology"},{"key":"464_CR152","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-10-0712","volume":"16","author":"W Peng","year":"2010","unstructured":"Peng, W. et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 16, 5458\u20135468 (2010).","journal-title":"Clin. Cancer Res."},{"key":"464_CR153","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon, E. K. et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17, 4719\u20134730 (2011).","journal-title":"Clin. Cancer Res."},{"key":"464_CR154","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346\u2013351 (2018).","journal-title":"Nat. Biotechnol."},{"issue":"26","key":"464_CR155","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"Christine E. Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. New Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"New England Journal of Medicine"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-0464-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-0464-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-0464-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:23:51Z","timestamp":1684617831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0464-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":155,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1038\/s41423-020-0464-1","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"31 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I. Melero is a paid consultant for Bristol-Myers Squibb, Roche, AstraZeneca, Pharmamar, Alligator, Numab, F-star, Servier, and MSD and reports receiving commercial research grants from Alligator, Bristol-Myers Squibb, Roche, and Pharmamar. No potential conflict of interest were disclosed by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}